# Human bone marrow-mesenchymal stem cells differentiation into brain-like endothelial cells

**Authors:** Yomna SOLIMAN, Gülin BARAN, Nur MUSTAFAOĞLU

PMC · DOI: 10.55730/1300-0152.2786 · 2025-08-05

## TL;DR

This study shows how bone marrow stem cells can be turned into brain-like blood vessel cells, which could help model the blood-brain barrier for drug testing and disease research.

## Contribution

A novel direct differentiation protocol for generating brain-like endothelial cells from MSCs, bypassing mesodermal induction.

## Key findings

- MSCs were successfully differentiated into BLECs expressing BMEC markers like ZO-1, CD31, and occludin.
- The protocol used hypoxia, retinoic acid, cobalt chloride, and sodium sulfite to promote endothelial specification.
- The resulting BLECs showed functional characteristics suitable for in vitro blood-brain barrier modeling.

## Abstract

Brain microvascular endothelial cells (BMECs), which constitute the blood–brain barrier (BBB), are essential for maintaining central nervous system homeostasis. Like BMECs, multipotent mesenchymal stem cells (MSCs) originate from the mesodermal lineage. Thus, MSCs may serve as a direct and efficient cellular source for BMEC-like differentiation. Notably, differentiation of human induced pluripotent stem cells (hiPSCs) into BMECs typically involves a 2-step protocol: inducing mesodermal commitment followed by endothelial specification. In contrast, direct differentiation from MSCs could bypass the initial mesodermal induction step, offering a streamlined alternative. This study tested a novel strategy for differentiating MSCs into brain-like endothelial cells (BLECs), circumventing the conventional mesodermal induction step.

Our differentiation protocol integrates developmental cues through the application of hypoxia, retinoic acid (RA), cobalt chloride (CoCl2), and—for the first time in this context—sodium sulfite (Na2SO3) to promote endothelial specification. Various basal media, including IMDM, EGM-2, and Endopan, were tested in combination with B27 supplement or fetal bovine serum (FBS) to optimize differentiation conditions. MSC viability under CoCl2 and Na2SO3 treatment was evaluated using the MTT assay to determine appropriate concentrations. The endothelial functionality of the resulting BLECs was assessed via tube formation assays.

Immunocytochemical analysis confirmed the expression of key BMEC markers, including ZO-1, CD31, and occludin, showing both phenotypic and functional characteristics of brain microvascular endothelium.

This MSC-based differentiation approach provides a robust and physiologically relevant in vitro BBB model with potential applications in studying neurological disease mechanisms and screening therapeutic agents.

## Linked entities

- **Proteins:** TJP1 (tight junction protein 1), PECAM1 (platelet and endothelial cell adhesion molecule 1), si:ch73-61d6.3 (uncharacterized si:ch73-61d6.3)
- **Chemicals:** retinoic acid (PubChem CID 444795), cobalt chloride (PubChem CID 24288), sodium sulfite (PubChem CID 24437)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** OCLN (occludin) [NCBI Gene 100506658] {aka BLCPMG, PPP1R115, PTORCH1}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, MRAP (melanocortin 2 receptor accessory protein) [NCBI Gene 56246] {aka B27, C21orf61, FALP, GCCD2, MRAP1}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}
- **Diseases:** neurological disease (MESH:D020271), hypoxia (MESH:D000860)
- **Chemicals:** Na2SO3 (MESH:C025026), CoCl2 (MESH:C018021), IMDM (-), RA (MESH:D014212), MTT (MESH:C070243)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12978769/full.md

---
Source: https://tomesphere.com/paper/PMC12978769